Ashland Inc. (ASH) has accelerated the application of its new super wetting technology platform, which was unveiled last September. The company has commercialized the easy-wet 300 n super wetting agent for corn, soy and wheat, as well as watermelon, flowers and other produce such as bananas, lettuce and tomatoes.  Successful field trials and client pilots over the last year have validated Ashland's strategy and demonstrated its commitment to rapidly scaling high-performance, creative and sustainable technol ...

Ashland Inc. (ASH) has announced that it completed the sale of its nutraceuticals business to an affiliate of Turnspire Capital Partners LLC on Aug. 30, 2024. The transaction includes custom formulation and contract manufacturing capabilities for the nutrition market from production facilities in New Jersey and Utah, the United States, as well as Tamaulipas, Mexico. The financial terms of the deal were not disclosed.The nutraceuticals business has a wide range of proprietary ingredients, formulations and ma ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores.What are t ...

Ashland Inc. (NYSE:ASH) Q3 2024 Earnings Conference Call August 7, 2024 10:00 AM ET Company Participants William Whitaker - Vice President-Finance and Director-Investor Relations Guillermo Novo - Chair of the Board and Chief Executive Officer Kevin Willis - Senior Vice President and Chief Financial Officer Conference Call Participants Christopher Parkinson - Wolfe Research John McNulty - BMO Capital Markets David Begleiter - Deutsche Bank Michael Sison - Wells Fargo Mike Harrison - Seaport Research Partners ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-211719 (a Delaware corporation) I.R.S. No. 81-2587835 8145 Blazer Drive Wilmington, Delaware 19808 Telephone Number (302) 995-300 ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?The Zacks ...

Ashland Inc. (ASH) recorded third-quarter fiscal 2024 (ended Jun 30, 2024) adjusted earnings of $1.49 per share, up from $1.23 in the prior-year quarter. The bottom line surpassed the Zacks Consensus Estimate of $1.47.Sales were down 0.4% year over year to $544 million. The top line missed the Zacks Consensus Estimate of $569 million. Higher volumes within the Personal Care and Specialty Additives segments were partly offset by reduced Life Sciences volumes. Pricing was weaker than the prior-year quarter.Se ...

Core Insights - For the quarter ended June 2024, Ashland reported revenue of $544 million, a decrease of 0.4% year-over-year, with EPS at $1.49 compared to $1.23 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $569.02 million by 4.40%, while the EPS exceeded the consensus estimate of $1.47 by 1.36% [1] Revenue Performance - Revenue from Intermediates was $36 million, below the average estimate of $40.87 million, representing a year-over-year decline of 16.3% [3] - Revenue from Specialty Additives was $150 million, slightly below the average estimate of $154.91 million, with a year-over-year decrease of 1.3% [4] - Revenue from Personal Care reached $175 million, surpassing the average estimate of $162.63 million, showing a year-over-year increase of 19.9% [5] - Revenue from Life Sciences was $195 million, below the estimated $220.99 million, reflecting an 11% decline year-over-year [6] Adjusted EBITDA Performance - Adjusted EBITDA for Life Sciences was $59 million, compared to the average estimate of $67.79 million [7] - Adjusted EBITDA for Intermediates was $9 million, below the average estimate of $12.20 million [8] - Adjusted EBITDA for Specialty Additives was $38 million, exceeding the average estimate of $33.68 million [9] - Adjusted EBITDA for Personal Care was $51 million, above the average estimate of $46.67 million [10] Stock Performance - Ashland's shares have returned -3.9% over the past month, compared to a -6.7% change in the Zacks S&P 500 composite [11] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [11]

Ashland (ASH) came out with quarterly earnings of $1.49 per share, beating the Zacks Consensus Estimate of $1.47 per share. This compares to earnings of $1.23 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.36%. A quarter ago, it was expected that this chemical company would post earnings of $1.19 per share when it actually produced earnings of $1.27, delivering a surprise of 6.72%.Over the last four quarters, the company ha ...

Exhibit 99.1 Ashland reports financial results1for third quarter fiscal 2024, issues outlook for fourth quarter and full-year fiscal 2024 • Sales of $544 million • Net income (including discontinued operations) of $6 million, or $0.12 per diluted share • Income from continuing operations of $31 million, or $0.60 per diluted share • Adjusted income from continuing operations excluding intangibles amortization expense of $75 million, or $1.49 per diluted share • Adjusted EBITDA of $139 million, up five percen ...